Neovascularization is vital for the growth of tumours, providing a lifeline for sustenance and waste disposal. Tumour vessels can grow by sprouting, intussusception or by incorporating bone marrowderived endothelial precursor cells into growing vessels. Recent advances in vascular biology have identified some key factors that control vascular growth, and have led to the hypothesis that in normal tissues vascular quiescence is maintained by the dominant influence of endogenous angiogenesis inhibitors over angiogenic stimuli. In contrast, increased secretion of angiogenic factors and the down-regulation of endogenous angiogenesis inhibitors induce tumour angiogenesis. Vascular quiescence in the skin seems to be primarily maintained by a balance between the endogenous angiogenesis inhibitors thrombospondin 1 and thrombospondin 2 and the potent proangiogenic factor vascular endothelial growth factor A. Inhibiting tumour growth by controlling angiogenesis is an intriguing approach with great potential for the treatment of vascular tumours such as haemangioma, Kaposi's sarcoma and solid cutaneous tumours such as squamous cell carcinoma, melanoma and basal cell carcinoma. In this review, the role of angiogenesis and more recent topics such as lymphangiogenesis in cutaneous tumour growth, invasion and metastasis will be discussed.
Human skin is a richly vascularized organ consisting of a superficial vascular plexus that is found directly beneath the epidermis and a deep vascular plexus located at the dermal-subcutaneous border. These vascular beds are tightly interconnected and play an important role in vital physiological processes of the skin such as the supply of nutrients, controlling the influx of immune cells, hair growth and thermoregulation. The development of the blood vasculature is a complex process that begins when progenitor cells (angioblasts) differentiate into endothelial cells, coalesce and form the first vessels in the embryo (vasculogenesis). These embryonic vascular tubes give rise to new vessels by branching or sprouting (angiogenesis) that in turn can elongate, enlarge, mature or regress (vascular remodelling) in response to different stimuli (reviewed by Carmeliet and Jain 1 ). Together, these processes are vital in the developing embryo but are mostly absent in the adult.
In normal and diseased skin, the angiogenic stimulus seems to originate from the epidermis and not the dermis. 2 This makes intuitive sense as the avascular epidermis would require mechanisms designed to meet the high metabolic demands associated with hyperproliferation in healing wounds, inflammation or neoplasms. Many potent proangiogenic factors such as basic fibroblast growth factor (FGF-2) [3] [4] [5] and chemokines such as interleukin (IL)-8 6, 7 have been described in cutaneous angiogenesis. However, vascular endothelial growth factor (VEGF)-A is regarded as the major angiogenesis factor in many cutaneous diseases, particularly in tumour growth. 8 VEGF-A is a homodimeric heparin-binding glycoprotein occurring in at least four isoforms as a result of alternative splicing. 9 It binds two type III tyrosine kinase receptors primarily expressed on vascular endothelial cells, VEGF receptor (VEGFR)-1, also termed fms-like-tyrosine kinase (Flt)-1, and VEGFR-2, 10-12 also known as kinase-insert domaincontaining receptor or fetal liver kinase-1, as well as the neuropilin receptors. 13 Several experimental models highlight the importance of VEGF-A as a potent proangiogenic and tumour growth factor (reviewed by Ferrara and Gerber 14 ) , and VEGF-A up-regulation is implicated in promoting tumour invasiveness. [15] [16] [17] VEGF-A secreted by tumour cells can induce the release of matrix metalloproteinases (MMPs) by endothelial cells. 18 Elevated levels of membrane type 1 MMP, MMP-2 and MMP-9 19 have been demonstrated to degrade the extracellular matrix, paving the way for the invasion of endothelial cells into the surrounding tissue. Furthermore, MMPs release sequestered angiogenic factors such as FGF-2 and VEGF-A from extracellular stores, thereby increasing their bioavailability (Table 1) . Conversely, MMP activity is important for the generation of endogenous angiogenesis inhibitors such as endostatin, which is a cleavage product of collagen XVIII. 20 Recently, the angiopoietin growth factor family has been shown to modulate vascular remodelling, leakage 21 and tumour growth. 22 Angiopoietin 1 (Ang-1), normally found on pericytes, binds the tyrosine-protein kinase receptor (Tie)-2 primarily expressed on endothelial cells and stabilizes the blood vessel. Angiopoietin 2 (Ang-2) is a competitive antagonist to Ang-1 and counters this stability. The vessel can undergo angiogenesis in the presence of a proangiogenic factor, or regress in its absence. 23, 24 Ang-2 and VEGFR-2 have been shown to be up-regulated in the very early stages of tumour growth and to be continuously overexpressed in the lesions, suggesting that these molecules work together to induce new vessel growth and remodel the tumour vasculature. 25 It is generally believed that in quiescent vessels, a balance between proangiogenic and antiangiogenic factors maintains homeostasis. Experimental data suggest that the Ôangiogenic switchÕ, the change from a quiescent tumour cell population to cells that can induce angiogenesis, is a rate-limiting step in the progression from a premalignant minimal lesion to a malignant invasive lesion. It is dependent on the up-regulation of angiogenic factors and the downregulation of inhibitors. 26 In the skin, aside from follicular-related angiogenesis in certain phases of the hair cycle, 27 the blood vessels remain quiescent and neovascularization is generally not seen. It has been suggested that the normal dermal matrix, in particular the basement membrane surrounding microvascular endothelial cells, may function as a natural inhibitor of angiogenesis, thereby ensuring the quiescence of vessels in healthy skin. Recent evidence suggests that thrombospondin (TSP)-1 and TSP-2 are major physiological inhibitors of skin angiogenesis. 28, 29 TSP-1 and TSP-2 are members of a family of matrix glycoproteins and are deposited in the dermoepidermal basement membrane, 30 thereby contributing to the antiangiogenic barrier that separates the avascular epidermis from the vascularized dermis. 28 Furthermore, these endogenous angiogenesis inhibitors, [31] [32] [33] [34] as well as endostatin, 20 angiostatin, 35 vasostatin 36 and IL-12, 37 have been identified as inhibitors of tumour angiogenesis and tumour growth in vivo (Table 2) . Early metastasis to the lymph nodes as well as the presence of dilated peritumour lymphatic vessels in melanoma and other tumours 38 led to rising interest in investigations of tumour lymphangiogenesis. (2, 9) Remodel extracellular matrix, release and activate growth factors
Important for the formation, survival and maturation of new blood vessels and potential modulators of EC invasion
H, haemangioma; K, Kaposi's sarcoma; M, melanoma; S, squamous cell carcinoma; B, basal cell carcinoma; FGF-2, basic fibroblast growth factor; VEGF, vascular endothelial growth factor; PlGF, placenta-derived growth factor; PDGF, platelet-derived growth factor; IL, interleukin; MMPs, matrix metalloproteinases; Ang, angiopoietin; EC, endothelial cell.
VEGF-C was the first lymphangiogenesis factor described. 39, 40 It binds to VEGFR-3, also known as Flt-4, normally expressed exclusively on the lymphatic endothelium, and to VEGFR-2.
39,40 VEGF-C has recently been demonstrated to promote tumour lymphangiogenesis, angiogenesis and metastasis. [41] [42] [43] [44] The recent discovery of specific markers for lymphatic vessels such as the lymphatic vessel endothelial hyaluronan receptor-1 45 and the homeobox gene PROX1 46 promises to facilitate studies of lymphangiogenesis in tumour biology.
Angiogenesis in vascular tumours of the skin
There are several described benign cutaneous vascular neoplasms such as pyogenic granuloma and angiokeratoma as well as malignant vascular tumours such as angiosarcoma, yet most studies concerning angiogenesis in cutaneous vascular tumours have been performed using haemangioma and Kaposi's sarcoma (KS) as models.
Haemangioma is the most common neoplasm of infancy. This endothelial tumour undergoes a proliferative phase followed by an involution phase leading to the spontaneous regression of the lesion (involuted haemangioma). Normally haemangioma presents no medical threat but sometimes the fast-growing nature of this tumour can interfere with normal functions. The most common complications are circulatory problems arising from high shunt volumes or vision impairment resulting from the physical obstruction of the eye. Furthermore, trauma of extensive haemangiomas can cause pronounced bleeding. In some cases haemangiomas can develop into severe diseases such as Kasabach-Meritt syndrome where dysfunction of the coagulation system can be lethal.
Proliferating haemangiomas are composed of densely packed endothelial cells with little connective tissue and barely discernible vessel lumina. This hyperproliferative endothelial cell population has recently been demonstrated to be clonal, originating from a progenitor cell that could have a mutated angiogenesis regulation gene. A second group has suggested that the clonal cell population could arise from one or a few placental endothelial cells that have migrated into the fetal circulation from chorionic villi (reviewed by Marchuk 47 ). Proliferating haemangiomas overexpress a plethora of angiogenesis activators (Table 1) . Among them are FGF-2, 48 monocyte chemoattractant protein-1 49 and VEGF-A. 5 However, low expression levels of VEGF-A in haemangioma-derived endothelial cells and in proliferating lesions have recently been reported. This study identifies the angiopoietins as potential modulators in the pathological growth and vascular remodelling evident in haemangioma. 50 The group reports upregulation of Tie-2 expression both in the haemangioma-derived endothelial cells and in the proliferating lesions. 50 Notably, previous studies have linked Tie-2 expression abnormalities to other venous malformations. 51 A small number of thin-walled vessels that resemble normal capillaries surrounded by regions of fibrofatty tissue characterizes involuting and involuted haemangioma. Interestingly, during this phase the expression levels of the endogenous angiogenesis suppressors tissue inhibitor of MMP (TIMP)-1 and interferon (IFN)-b are up-regulated when compared with the proliferative phase. 48, 52 Clinically, corticosteroid therapy and the angiogenesis inhibitor IFN-a are used as therapeutic agents for life-threatening haemangioma. However, because of side-effects and inconsistent success rates, new therapies are still necessary. Both endogenous and exogenous angiogenesis inhibitors have been reported successfully to reduce the experimental tumour growth of haemangioma (Table 2) . Angiostatin has been found to inhibit murine haemangioendothelioma growth. 53 TIMP-2 54 and a VEGF-toxin conjugate, 55 as well as synthetic compounds such as TNP-470 (a derivative of fumagillin) 56 and batimastat (a synthetic MMP inhibitor) 57 have been reported effectively to reduce experimental tumour growth. Understanding the cellular and biochemical mechanisms that control the growth and spontaneous regression of haemangioma would provide critical insights into aberrant angiogenesis and the mechanisms that exist to override this defect. It seems important to investigate whether at later stages in childhood, endogenous angiogenesis inhibitors are naturally up-regulated in order to counteract the angiogenic stimuli necessary for growth during childhood. This could explain the spontaneous regression of haemangioma.
KS is an angiogenic tumour affecting mostly the skin and mucosa. It is found endogenously among several ethnic groups but is more commonly associated with immunological disorders arising from organ transplants and human immunodeficiency virus (HIV) infection. 58, 59 It is vascular in origin with tumours consisting mainly of hyperproliferative spindle-shaped tumour cells, inflammatory cell infiltrate and numerous blood vessels, and is frequently accompanied by extensive oedema. 60 Many factors and cytokines that promote angiogenesis, lymphangiogenesis and vascular remodelling are known to be overexpressed in KS cells and lesions (Table 1) . Among them are VEGF-A, 61 FGF-2, 3 IL-6 62 and IL-8. 6 Recently, IL-8 has been identified as an important angiogenesis factor and autocrine growth factor in KS, as the functional inhibition of this proinflammatory cytokine using a neutralizing antibody resulted in a significant inhibition of experimental tumour growth. 6 Additionally, strong overexpression of Ang-2, Tie-1 and Tie-2 highlights a potential role of the angiopoietin family in the pathobiology of both KS and angiosarcoma. 63 Lastly, it has been suggested that VEGF-C acts as a paracrine growth factor for KS because its receptors VEGFR-2 and VEGFR-3 have been demonstrated to be overexpressed by KS tumour cells. 64 In vitro, VEGF-C has been shown to stimulate the migration and proliferation of KS cells. 65 As the expression of VEGF-C and VEGFR-3 is normally confined to the lymphatic endothelium, it has been suggested that KS cells might be of lymphatic origin. 64 There is convincing evidence that the angiogenic activity of KS cells is linked to viral infection. Human herpesvirus 8 (HHV-8) expression is found in both endogenous and induced KS and is thought to stimulate the release of inflammatory cytokines that can convert nascent endothelial cells into KS-like spindle cells. 66 Furthermore, HHV-8-transformed endothelial cells overexpress VEGF-A, VEGF-C and VEGF-D. 67 However, KS is more common and aggressive in conjunction with HIV infection. In fact, HIV-1-infected T cells secrete a transactivator of viral gene expression (Tat), a protein that promotes the migration, invasion, growth and adhesion of the spindle cells and tumourrelated endothelial cells in vitro. 68 Tat evokes a pronounced angiogenic effect on endothelial cells when combined with inflammatory cytokines 68 such as IL1b, tumour necrosis factor-a and IFN-c, and synergizes with FGF-2 in vivo. 69 Evidently, KS is a model for altered angiogenesis as a result of either viral infection or immunosuppressive therapy. Additional investigations of this tumour might elucidate this link and reveal its potential relevance in other cutaneous tumours.
Highly vascularized tumours such as KS are good candidates for therapeutic angiogenesis inhibition. In fact, many experimental approaches have been investigated to treat KS with both endogenous and synthetic angiogenesis inhibitors (Table 2) . TSP-1, 70 IFN-a and IFN-b 71 have been shown to inhibit angiogenesis and diminish tumour growth in KS. These endogenous angiogenesis inhibitors are thought to suppress the proangiogenic Tat protein. 71, 72 Furthermore, IFN-a and IFN-b directly suppress the migration of endothelial cells and their organization into capillary-like structures. 72 IFN-b also down-regulates the expression of FGF-2 and lowers the production of MMP-2.
71 TSP-1 reportedly binds FGF-2 73 and modulates the production of MMP-2 and TIMP-2. 73 Other natural compounds such as antineoplastic urinary protein 74 have been shown to diminish experimental KS growth. Furthermore, gene therapy approaches have been created whereby IFN-or angiostatin-producing cells are implanted into KS-bearing mice, resulting in inhibition of both angiogenesis and tumour growth. 73, 75 Recently, the HIV proteinase inhibitors indinavir and saquinavir have been shown to exert a potent antiangiogenic and antitumour effect on experimental KS, suggesting that these molecules could be used in the treatment of other HIV-related tumours and in non-HIV KS. 76 82 have been found to act as angiogenesis inhibitors in KS and angiosarcoma tumour growth. 83 
Angiogenesis in squamous cell carcinoma
Squamous cell carcinoma (SCC) is a malignant cancer of the epidermal keratinocytes with a destructive growth pattern and the ability to metastasize. Its development is a multistep process, in which cells accumulate genetic alterations thereby gradually converting from normal to malignant cells. In humans, 60% of cutaneous SCCs develop from actinic keratoses. These premalignant lesions exhibit up to 20% probability of becoming malignant 84 and carry similar genetic changes also found in SCCs, such as mutations in the p53 tumour suppressor gene. 85 The VEGF family has been shown to play a fundamental role in the growth and invasion of SCC. The experimental overexpression of VEGF-A alone in a nonaggressive SCC clone could induce tumour growth and invasion in vivo. 17 Moreover, blocking VEGFR-2 function using a neutralizing antibody resulted in the inhibition of angiogenesis and invasion of malignant SCC. 86 VEGFR-2 expression has been shown to be transiently up-regulated in actinic keratosis and to be continuously overexpressed in malignant lesions, suggesting a key role of the receptor in SCC tumorigenicity. 86 Meanwhile, VEGF-A expression levels in premalignant and malignant lesions have been reported to be similar. 87 In these tumour biopsies, increased neovascularization has been observed only in the later stages of the tumour, indicating a late onset of the angiogenic switch. 87 Yet, in a transgenic model, the angiogenic switch in SCC was reported to occur early, before a malignant lesion was evident. 26 Interestingly, a recent report shows that VEGFR-2 up-regulation in experimental tumours occurs earlier than the upregulation of VEGF-A. The group concludes that as low levels of VEGF-A can normally be found in tumours, the rate-limiting step for tumour angiogenesis is the induction of VEGFR-2. 25 TSP-1 and TSP-2 expression in the basement membrane separating the dermis from the epidermis is lost in invasive SCC, suggesting that the down-regulation of TSP-1 and TSP-2 is a requisite step for SCC invasion. 29 Interestingly, some SCC cell lines have a deletion in chromosome 15, where the TSP-1 gene has been mapped. 32 Adding a copy of chromosome 15 or TSP-1 to one of these cell lines resulted in tumour growth suppression. These experiments provide convincing evidence that the aberrant expression of this endogenous angiogenesis inhibitor is an important aspect of SCC. 32 Furthermore, Streit et al. demonstrated that the experimental growth of SCC is significantly inhibited when the cells overexpress TSP-1 and ⁄ or TSP-2. 33, 34 In fact, cell-based antiangiogenic gene therapy of SCC has resulted in the successful inhibition of experimental tumour growth using TSP-2-and angiostatin-producing cells. 88 Recently, Ang-1-overexpressing SCC cells were shown to have diminished tumour growth. 89 No major changes in the vascular density were found in these tumours, suggesting that other vascular mechanisms could be responsible for the observed inhibition. Interestingly, a higher number of mature vessels composed of endothelial cells closely associated with pericytes was reported in these tumours. Previous studies have shown that mature vessels have a diminished ability to sprout and form new capillaries [90] [91] [92] and, furthermore, have been found in other tumours subjected to antiangiogenesis treatment. 93 
Angiogenesis in melanoma
Cutaneous malignant melanoma is known for its poor prognosis and high resistance to treatment as well as its steadily increasing incidence rate. Distinct sequential steps from a common acquired melanocytic naevus to a dysplastic naevus leading to a radial growth phase primary melanoma characterize the progression of tumour malignancy. This primary phase is followed by a vertical growth phase that is linked to high angiogenic activity and can result in metastasis. 94 Melanoma tends to spread via the lymphatic vessels to the area surrounding the tumour and to the draining lymph nodes. In later stages, melanoma cells metastasize distal from the primary tumour mainly to the lung, cerebrum and liver. Conventional chemotherapy treatments currently available are not very promising and many research efforts address potential alternative therapies.
Many potent angiogenesis factors such as VEGF-A, 95, 96 FGF-2, 4 IL-8, 7 placenta-derived growth factor 97 and Ang-2 22 have been observed in human melanoma cells and tumours (Table 1) . VEGF-A-transfected melanomas are characterized by increased angiogenesis and tumour growth. 95 Furthermore, melanoma cell lines that develop low metastatic experimental tumours express low levels of VEGF-A compared with high metastatic tumour xenografts. 15 Importantly, several receptors previously thought to be exclusively expressed on endothelial cells such as VEGFR-1, VEGFR-2 and Tie-2 are also expressed on different tumour cells. Therefore, growth factors formerly described as specific endothelium modulators are less particular than previously believed. In fact, in addition to proangiogenic roles, VEGF-A, FGF-2 and IL-8 function as autocrine and paracrine growth factors in melanoma. Moreover, functional blocking studies of these factors using neutralizing antibodies resulted in the inhibition of melanoma metastasis. 7 Recent experiments implicate the Tie-2 signal pathway as an important angiogenesis modulator in melanoma. Blocking the Tie-2 signal using dominant-negative receptor domains 98 and using an adenoviral vector to deliver recombinant soluble Tie-2 resulted in the inhibition of experimental melanoma growth. 99 Several reports indicate that the expression of the integrin avb3 correlates with the vertical growth phase of melanoma and could play a role in the progression of the tumour. 100 Functional blocking studies using antibodies directed against the avb3 integrin inhibited the experimental growth of melanoma. 101 The integrin family of cell adhesion receptors mediates cellular interaction with the extracellular matrix and is required for angiogenesis. 102 Several experimental approaches to treat melanoma using angiogenesis inhibitors have been reported. The endogenous inhibitors TSP-1, 103 113 This report demonstrates the unexpected side-effects that can result from the therapeutic use of these novel compounds.
The importance of lymphangiogenesis in the spread of melanoma has recently been reported. VEGF-C is known to induce lymphatic and vascular endothelial cell proliferation in vivo and is expressed in human melanoma cells. 41, 114 Skobe et al. recently reported an increase in the number of both intratumour lymphatic and blood vessels using a VEGF-C-overexpressing melanoma model. 41 The authors and other groups 42, 43 have shown that overexpression of VEGF-C in different tumour models induced a significant increase of lung and lymph node metastasis, presumably through the tumour-associated lymphatic vessels. However, overexpression of VEGF-C did not result in an increase in the experimental growth of melanoma 41 or breast tumours. 42 Finally, VEGF-D has also been implicated in inducing lymphangiogenesis in melanoma. VEGF-D is expressed in the lesions 115 and blocking its activity diminished experimental metastasis, suggesting that this factor might be involved in the spread of melanoma. 116 
Angiogenesis in basal cell carcinoma
Basal cell carcinoma (BCC) is the most common cutaneous cancer found in humans. This well-vascularized and slow-growing tumour generally follows a relatively benign course, although in some cases BCC can become aggressive, invade deeper skin structures and even metastasize. However, few studies have addressed the role of angiogenesis in BCC.
VEGF-A is normally absent in BCC. Yet, in contrast to nascent BCC tumour cells, IL-6-transfected cells demonstrated accelerated growth and tended to invade the area around the xenotransplant in mice. Tumour cells in these lesions expressed VEGF-A, 16 thereby providing further evidence that the expression of VEGF-A is important for tumour growth and tumour invasion. Macroscopic telangiectasias are a hallmark of BCC. These superficially visible blood vessels allow for a relatively simple method to observe and quantify blood vessels during tumour development, making BCC a possible model to study the effects of angiogenesis inhibition on tumour microcirculation. 117 Further research will clarify the role of angiogenesis in BCC and elucidate whether the onset of the angiogenic switch is linked to the increasingly aggressive phenotype sometimes evident in this tumour.
Angiogenesis in cutaneous lymphomas
Although few studies address the role of angiogenesis in lymphoproliferative diseases of the skin, a correlation between microvascular density (MVD) and growth dynamics of cutaneous lymphomas has recently been described. Vacca et al. have shown that the MVD and the expression of angiogenesis inducers such as MMP-2 and MMP-9 undergo significant up-regulation in relation to advancing stages of mycosis fungoides. 118 Similar results relating vascular density and the aggressiveness of cutaneous B-cell lymphomas have been reported. 119 Interestingly, little is known about angiogenesis factors or inhibitors in cutaneous lymphomas. The lack of alternative treatment options for cutaneous lymphoma and the long duration of this disease call for new therapy concepts. Angiogenesis inhibitors could be used in the early stages of the disease in order to keep the tumour in a dormant state, preventing the onset of the angiogenic switch. To date, there is no evidence of drug resistance to angiogenesis inhibitors, making them an appealing choice for long-term treatments particularly in slow-developing tumours. 120 Angiogenesis as a significant prognostic factor?
In the last decade, several studies have revealed a correlation between an increase in intratumour MVD and different parameters of tumour aggressiveness, metastasis and patient survival. 121 However, there are contradictory reports showing no such correlation. 122, 123 These discrepancies could be a result of the methodology selected by different researchers or variations in the tumour stage of investigated samples. In the skin, haemangioma and pyogenic granuloma are examples of extremely well-vascularized fast-growing cutaneous tumours that are nonetheless benign and non-invasive. Additionally, the MVD in premalignant keratoacanthoma and SCC is similar, showing no relationship with tumour progression. [123] [124] [125] These observations question the validity of MVD as a reliable parameter for the grade of malignancy or prognosis in cutaneous tumours. In melanoma, the expression patterns of factors responsible for angiogenesis and invasion such as VEGF-A, FGF-2 and IL-8 are a useful prognostic tool 126 that could perhaps improve future clinical diagnosis for different malignancies. Moreover, lymphatic vessel density and lymphatic growth factor expression might some day be a valuable prognostic tool for patient outcome. 127 
Angiogenesis inhibitors in clinical trials
There are currently several ongoing clinical trials using antiangiogenic substances either alone or in combination with conventional therapies targeting different cutaneous tumours such as melanoma, KS and T-cell lymphoma. These trials are based on different experimental strategies for angiogenesis inhibition. Some compounds interfere with proangiogenic ligands, their receptors or downstream signals (SU5416). Others upregulate or deliver endogenous angiogenesis inhibitors (IL-12) or directly target the tumour vasculature (thalidomide). Previous trials have reported a partial response in the treatment of KS using thalidomide 128 and stabilization of melanoma patients using carboxyamidotriazole, an inhibitor of calcium-mediated signal transduction. 129, 130 Table 3 lists substances currently undergoing clinical trials. However, most of the compounds listed are in phase II trials and the outcome for cutaneous tumours has not yet been evaluated (more detailed and up-to-date information is available at www.nci.nih.gov/clinical_trials).
Interestingly, several angiogenesis inhibitors have proven unsuccessful in clinical trials. These failures could result from potential problems such as dosage, formulation or drug delivery strategies. Moreover, during tumour growth a variety of angiogenic molecules is produced by both stroma and tumour cells. Blocking the function of one of these molecules may not successfully eradicate the tumour as other factors may be up-regulated and counter the inhibitory effect. Perhaps a mixture of compounds blocking several angiogenic pathways might be the best therapeutic approach.
Other factors may account for the discrepancy between experimental results and the outcome of human clinical trials. Preclinical data are gathered in immune compromised mice with specially selected fastgrowing tumour cell lines. The short experimental treatment often commences before or at the time of tumour cell inoculation, whereas oncology treatment in humans involves drug administration over several years beginning once the tumour has been detected. 131 while endostatin and vasostatin treatment did not affect cutaneous wound healing at tumour-inhibiting doses. 93, 132 Finally, new experimental strategies seek to influence other vascular parameters such as leakage or the maturation status of blood vessels in order to diminish the sprouting capability of capillaries. Furthermore, new approaches have targeted the tumour vasculature based on the assumption that most endothelial cells in tumours express distinct markers (Ôzip codesÕ). Identifying this heterogeneous group of surface molecules on different endothelial cell populations 133 could be useful for more precise drug targeting strategies. 134 
Implications of angiogenesis in dermatology
Many cutaneous diseases could potentially benefit from antiangiogenic treatments. Potential targets include the vascular tumours discussed and less common tumours such as angiokeratoma. Moreover, therapeutic neovascularization and its inhibition is not only restricted to neoplastic skin diseases. Blood vessels are involved in a variety of cutaneous diseases and are often of essential diagnostic value. Different types of vessel growth can be observed in diseased skin. For example, telangiectasias are smaller forms of neovascularization and are a hallmark of certain pathologies such as rosacea or cutaneous autoimmune disease. Dilated, elongated and tortuous blood vessels are a typical feature of inflammatory diseases such as psoriasis. Subsequent investigations will elucidate the potential value of treating inflammatory disorders of the skin by blocking angiogenesis. Other potential targets include fast-growing hypertrophic scars and keloids that could be equally dependent on a vascular supply. Furthermore, the administration of angiogenesis factors on chronically impaired healing wounds such as diabetic ulcers might stimulate the formation of granulation tissue and thereby improve the overall wound healing process. It has been recently reported that angiogenesis plays an important role in ultraviolet-induced skin ageing 135 and hair growth. 27 Further studies are necessary to reveal whether modulating angiogenesis can successfully influence these processes. Ongoing and future clinical studies will reveal the potential of antiangiogenic and proangiogenic therapies for the treatment of cutaneous pathologies.
Skin angiogenesis is easily visualized and facilitates the use of techniques such as surgically created windows or intravital microscopy to quantify blood vessel growth and to study the function of blood vessels in tumours. Both neovascularization and angiogenesis inhibition can be directly observed in the skin. This characteristic has made the skin an attractive organ for the development of experimental assays such as carcinogenesis and orthotopic tumour growth. These experimental approaches can be combined with therapeutic trials to test the effects of substances such as angiogenesis inhibitors. Dermatologists face the challenge to develop drug delivery systems for locally administered angiogenesis factors and inhibitors avoiding systemic side-effects. Lastly, only the dermatologist can identify the wide range of cutaneous diseases that could potentially benefit from this novel treatment concept.
